Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis
Related Experiment Videos
Ralph Melchior1, Bernard Zabel, Jürgen Spranger
1Children's Hospital, Klinikum Kassel, Kassel, Germany. ralphmelchior@aol.com
Insights
Parenteral clodronate effectively treated severe idiopathic juvenile osteoporosis (IJO) in a young boy, resolving fractures and improving bone density. The treatment showed sustained benefits, even after discontinuation, highlighting its therapeutic potential.
Area of Science:
- Pediatric Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Idiopathic juvenile osteoporosis (IJO) is a rare, severe bone disorder in children.
- Characterized by fractures and bone resorption, IJO typically resolves post-puberty but can necessitate intervention.
- This case highlights the challenges in managing severe IJO manifestations.
Observation:
- An 8-year-old boy presented with severe IJO, multiple fractures (vertebral), and neurological symptoms.
- Biological findings revealed excessive bone resorption and significant urinary calcium loss.
- Initial treatment involved parenteral clodronate (dichloromethylene-bisphosphonate) every 3 months for 2 years.
Findings:
- Rapid clinical and biochemical improvement occurred within 2 weeks of clodronate administration.
- Bone resorption markers normalized, and no new fractures were observed.
- Radiological healing, vertebral plate rebuilding, normalized bone mineral density, and accelerated growth were documented within 1-2 years.
Implications:
- Parenteral clodronate is a highly effective treatment for severe idiopathic juvenile osteoporosis.
- The therapy demonstrated sustained efficacy, with rapid improvement upon re-administration after relapse.
- No adverse effects were noted, suggesting a favorable safety profile for clodronate in pediatric IJO management.
Unlabelled:
We report on an 8 years and 3 months old boy with severe idiopathic juvenile osteoporosis (IJO). Clinical features included multiple fractures, especially of the vertebrae, and neurological symptoms. Biological studies showed non-parathyroid hormone-mediated excessive bone resorption and massive urinary calcium loss. Although IJO is usually a self-limiting condition after puberty, the severity of our patient's manifestations required therapeutic intervention. Clodronate (dichloromethylene-bisphosphonate) was administered parenterally every 3 months for a period of 2 years. Dramatic clinical and biochemical improvement was noted within 2 weeks. All parameters of bone resorption normalised and no new fractures occurred. After 6 months of treatment, radiological improvement with healing of fractures and rebuilding of the vertebral plates was documented. Bone mineral density increased to normal within 1 year and growth velocity was accelerated. After 2 years, treatment was stopped at the age of 10 years and 3 months. One year later, back pain and increasing pain in the knee region recurred. A tibial fracture was evident and, again, bone mineral density was far below normal. Bisphosphonate medication was reinstituted leading to rapid improvement. No side-effects were observed.
Conclusion:
Parenteral clodronate therapy is effective in managing severe idiopathic juvenile osteoporosis.
Related Concept Videos
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption